About Us

LCT is an Australasian biotechnology company improving the wellbeing of people with serious diseases by discovering, developing and commercialising novel treatments for debilitating conditions.

Product candidates include:

  • NTCELL, an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells targeting Parkinson’s disease.  

LCT is listed on the Australian (ASX: LCT) and US (OTCQB: LVCLY) stock exchanges and is incorporated in Australia, with operations based in Australia and New Zealand.